PCAS NET SALES as OF 30 SeptembeR, 2016
Longjumeau, November 3, 2016
PCAS (Euronext Paris: PCA), a specialist in developing and producing complex molecules for life sciences and innovative technologies, has announced the publication of its consolidated net sales as of 30 September, 2016.
The PCAS Group had generated consolidated net sales of €134.1 million as of 30 September, 2016, representing growth of +8.5% compared to the same period during the previous financial year (+7.5% at a constant exchange rate).
| in millions of euros | 2016 | 2015 | Growth in % | 2016 At a constant exchange rate | Growth in % | |||||
| Net sales as of 30 September | 134.1 | 123.5 | 8.5% | 132.8 | 7.5% | |||||
| Pharmaceutical Synthesis | 88.2 | 80.1 | 10.1% | 86.9 | 8.6% | |||||
| Fine Specialty Chemicals | 45.9 | 43.5 | 5.6% | 45.8 | 5.5% |
Vincent Touraille, Chief Executive Officer of PCAS, explains: "Our business growth levelled off during the third quarter of 2016 compared to the same period during the previous financial year. Nevertheless, we are reasonably confident that we will achieve our objective of increasing our net sales in both Pharmaceutical Synthesis and Fine Specialty Chemicals, as well as improving results throughout 2016 compared to 2015".
Pharmaceutical Synthesis
The Pharmaceutical Synthesis business generated €88.2 million, up +10.1% on 2015 (+8.6% at a constant exchange rate), which was especially driven by the Exclusive activity.
Fine Specialty Chemicals
Net sales of Fine Specialty Chemicals amounted to €45.9 million, up 5.6% on 2015 (+5.5% at a constant exchange rate), with growth in both Performance Additives and Advanced Specialty Chemicals.
| NEXT FINANCIAL DISCLOSURE: | |
| Net sales 2016, January 31, 2017 |
ABOUT PCAS
PCAS specializes in the development and production of complex molecules for life sciences and innovative technologies. With 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. Boasting especially high standards, the company offers of a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. PCAS generated net sales of €179.1 million in 2015 and employs close to 900 people in six countries.
To find out more about PCAS, visit: www.pcas.com
| PCAS | NewCap |
| Vincent Touraille / Eric Moissenot PCAS | Emmanuel Huynh / Louis-Victor Delouvrier NewCap Financial communication and Investor Relations |
| Tel. : +33 1 69 79 61 32 www.pcas.com | Tel. : +33 1 44 71 98 53 pcas@newcap.eu |
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: PCAS via Globenewswire
